The U.S. House of Representatives today passed H.R. 2900, also known as the. "FDA Amendments Act of 2007", by a vote of 403-16. The legislation originated with the Committee on Energy and Commerce's Subcommittee on Health. It improves current drug safety provisions, encourages greater transparency and timeliness in the drug review process, and reauthorizes the Food and Drug Administration's essential user fee programs.
"This bipartisan legislation provides FDA with the resources it needs to fulfill its mission of protecting the health of American consumers," said Rep. John D. Dingell (D-MI), Chairman of the Committee on Energy and Commerce. "By approving this comprehensive bill, Congress is striking the proper balance between new drug safety measures and consumer needs."
"Today, the House paved the way for restoring public confidence in the FDA by giving it the tools it needs to safeguard the public health," said Rep. Frank Pallone (D-NJ), Chairman of the Health Subcommittee. "We have produced a bipartisan bill that gives FDA the authority and resources it needs to ensure American consumers have timely access to safe and effective prescription drugs and medical devices."
Additional information on H.R. 2900, as well as the floor statement Rep. Dingell delivered today in support of this legislation, is available at: http://energycommerce.house.gov.
BREAK IN TRANSCRIPT